DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease — Stella

Recruiting

Back to Perianal Fistula Due to Crohn's Disease trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Direct Biologics Investigational Site, Aurora, Colorado

Direct Biologics Investigational Site, St Louis, Missouri

Columbia University Irving Medical Center/NYPH, New York, New York

Key details

Phase

Safety & dosing

Sponsor

Direct Biologics, LLC

Enrollment target

~36 participants

Started

May 2025

Primary completion

April 2026

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov